




FIG. 1

Lead-In Phase

Study Stage	Screening			In-patient														
Study Visit Week																		
	D-1	D1	D2	D5	D8	D11	W2		W3		W4	W6	W8	W12	W16	W20	W24- W32	W36 (EOS/ET)
Study Visit Day ± Visit Window																		
Informed consent	X																	
Demography	X																	
Medical history	X																	
Inclusion criteria	X																	
Physical examination (full physical on D1 and W36; symptom-directed on other days)	X	X	X (Daily)				X		X	X								X
Body weight, height, and BMI	X																	
Vital signs (including O2 saturation)	X	X ^a	X (every 8 hrs)				X		X	X								
Laboratory assessments (safety)	X	X							X	X								
Pregnancy test	X																	
Randomization		X																
Study drug administration		X																
Electrocardiogram	X		X (Daily)															
Blood sample for PK analysis (intensive) ^b		X ^c	X	X	X		X			X	X	X	X	X	X	X		X
Anti-drug Antibody (serum) (intensive) ^b		X ^d								X				X	X	X		X
Blood sample for anti-SARS-CpV-2 antibody		X			X		X			X				X				X
Blood sample for virology (e.g. viral analysis)		X			X		X			X								X
Blood sample for FcR and IgG analysis		X ^d																
Blood sample for RNA Paxgene		X ^d			X													
SARS-Cov-2 diagnostic test (point-of care or local laboratory test)	X																	

FIG. 2A

3/9

Study Stage	Screening	In-patient		Follow-up Period													
Study Visit Week						W2		W3		W4	W6	W8	W12	W16	W20	W24- W32	W36 (EOS/ET)
Study Visit Day ± Visit Window	D-1	D1	D2	D5	D8	D11	D15±2	D18±2	D22±2	D29±2	D43±3	D57±4	D85±7	D113±7	D141±7		D252±7
Nasal swab for virology		X	X	X	X	X	X	X	X	X							
Nasopharyngeal swab for virology		X			X		X		X	X							
Symptom self-assessment (daily)										X							
Monthly Phone call - safety assessment													X	X	X	X	X
Review/record AEs ^e													X				
Concomitant medications													X				
Blood sample for exploratory immunology (serum)		X ^d			X												
PBMC sample for immunology sub-study ^f		X ^d									X						X

^a Vital signs on day 1 will be q15 mins during IV infusion of drug, q1hr x 2hrs after infusion
^b All 20 participants in the lead-in (N=10/arm) will be included in an intensive PK and ADA sub study.
^c On Day 1, blood samples will be collected pre-dose and at end infusion, 1, 2, 6, and 12 hours following end of infusion
^d On Day 1, samples will be collected pre-dose
^e Adverse events will be assessed up to Week 12 post dose. Serious adverse events (SAEs) will be assessed up Week 36 (EOS) post dose.
^f Samples for optional immunology sub-study

Expansion Phase

Study Stage	Screening	Dosing	Follow-up Period												
Study Visit Week			W2			W3	W4	W8	W12	W16	W20	W24- W32	W36 (EOS/ET)		
Study Visit Day ± Visit Window	D-1	D1	D2	D5	D8±2	D11±2	D15±2	D18±2	D22±2	D29±2	D57±4	D85±7	D113±7	D141±7	D252±7
Informed consent	X														
Demography	X														
Medical history	X														
Inclusion criteria	X														

FIG. 2B

4/9

Study Stage		Screening	Dosing			Follow-up Period												
Study Visit Week			W1			W2		W3		W4	W8	W12	W16	W20	W24- W32	W36 (EOS/ET)		
Study Visit Day	Visit Window	D-1	D1	D2	D5	D8±2	D11±2	D15±2	D18±2	D22±2	D29±2	D57±4	D85±7	D113±7	D141±7	D252±7		
Physical examination (full physical on D1 and W36; symptom-directed on other days)		X	X	X		X		X		X	X					X		
Body weight, height, and BMI		X																
Vital signs (including O2 saturation)		X	X ^a			X		X		X	X							
Laboratory assessments		X				X		X		X	X							
Pregnancy test		X																
Randomization			X															
Study drug administration			X															
Blood sample for PK analysis (Sparse)			X ^c			X		X			X		X		X	X		
Anti-drug Antibody (serum) (Sparse)			X ^b								X		X		X	X		
Blood sample for anti-SARS-CpV-2 antibody			X			X		X		X	X		X			X		
Blood sample for virology (e.g. viral load)			X			X		X		X	X							
Blood sample for FcR and IgG analysis			X ^b															
Blood sample for RNA Paxgene			X ^b			X												
SARS-Cov-2 diagnostic test (point-of-care or local laboratory test)	X																	
Nasal swab for virology			X	X	X	X	X	X	X	X	X							
Nasopharyngeal swab for virology			X			X		X		X	X							
Symptom self-assessment (daily)			X	X	X	X		X										
Phone call - clinical symptom assessment						X (daily) ^d												

FIG. 2C

Study Stage	Screening	Dosing		Follow-up Period											
		W1		W2		W3		W4	W6	W8	W12	W16	W20	W24- W32	W36 (EOS/ET)
Study Visit Week		D1	D2	D5	D8±2	D11±2	D15±2	D18±2	D22±2	D29±2	D43±3	D57±4	D85±7	D113±7	D141±7
Study Visit Day	Visit Window	D-1													
Home Oxygen Saturation assessment															
Monthly Phone call-safety assessment															
Review/record AEs ^e															
Concomitant medications															
Work Productivity (WPAI)															
EQ-5D-5L															
Blood sample for exploratory immunology															
PBMC sample for immunology sub-study ^f															
^a Vital signs on day 1 will be q15 mins during IV infusion of drug, q1hr x 2hrs after infusion															
^b On Day 1, samples will be collected pre-dose															
^c On Day 1, collection will occur pre-dose and at the end of infusion															
^d Phone calls only on days when not evaluated in clinic.															
^e Adverse events will be assessed up to Week 12 post dose. Serious adverse events (SAEs) will be assessed up to Week 36 (EOS) post dose.															
^f Samples for optional immunology sub-study															

FIG. 2D




FIG. 3




FIG. 4




FIG. 5




FIG. 6